Research Suggests Widely Accepted Cholesterol and Blood Pressure Thresholds May Underestimate Cardiovascular Risk

For decades, a systolic blood pressure under 140 mmHg and an LDL cholesterol level under 130 mg/dL placed most adults squarely in the "normal" zone — numbers their doctors would note without concern. That consensus is fracturing. A convergence of large-scale trials, genetic studies, and updated professional guidelines now suggests those thresholds were too generous, and that millions of people who believed they were in the clear have been accumulating silent arterial damage for years.

The implications are clinical, financial, and political. If the evidence holds, the definition of who needs treatment is expanding — and not everyone agrees that expansion is a good thing.

The Thresholds Are Moving

The most concrete expression of this shift arrived in March 2026, when the American College of Cardiology and American Heart Association published a joint guideline on dyslipidemia management — the first comprehensive update since 2018 [1]. The new guideline establishes explicit LDL cholesterol target goals: below 100 mg/dL for adults at borderline or intermediate cardiovascular risk, below 70 mg/dL for those at high risk, and below 55 mg/dL for very-high-risk patients with established atherosclerotic cardiovascular disease (ASCVD) [1].

Source: ACC/AHA & ESC/EAS Guidelines

Data as of Jan 1, 2026CSV

These numbers represent a steady downward march. Before 2004, the recommended LDL-C ceiling for high-risk patients was 130 mg/dL. The ATP III update in 2004 dropped it to 100 mg/dL. The 2018 ACC/AHA guideline introduced a 70 mg/dL threshold for very-high-risk patients. Now, the 2026 guideline pushes the very-high-risk target to 55 mg/dL, and considers further intensification when LDL-C sits between 55 and 69 mg/dL [1].

Europe has gone further. The 2025 update to the European Society of Cardiology and European Association for the Study of Diabetes guidelines introduced an "extreme risk" category — patients with recurrent cardiovascular events — with a target of below 40 mg/dL [2]. That is less than one-third the level that would have been considered normal two decades ago.

Blood pressure thresholds followed a parallel trajectory. In 2017, the ACC/AHA redefined hypertension from a systolic reading of 140/90 mmHg down to 130/80 mmHg [3]. That single change reclassified an additional 31.1 million American adults — roughly the population of Texas — as hypertensive overnight [4]. More recently, the 2025 AHA/ACC hypertension guideline introduced a new risk estimation model called PREVENT, which incorporates kidney function, statin use, and social determinants of health into cardiovascular risk calculations [5].

Who Gets Reclassified — and Who Gets Left Behind

The population-level consequences of moving diagnostic thresholds are enormous. Under the old 140/90 definition, approximately 31.9% of U.S. adults had hypertension. Under the 130/80 standard, that figure jumps to 45.4% [4]. Among adults aged 65 to 74, the prevalence reaches 77.2%. Among non-Hispanic Black adults, it is 59% [6].

Source: Muntner et al., Circulation 2018

Data as of Jan 1, 2018CSV

Overall, 103.3 million U.S. adults met the 2017 hypertension criteria, of whom 81.9 million were recommended antihypertensive medication [4]. More recent CDC data puts the figure at nearly 120 million [6]. The 5.6 million newly classified Stage 1 hypertensive adults had an estimated 10-year ASCVD risk of 8.2% — not trivial, but also not high enough to justify pharmacotherapy for all of them under the guideline's own risk-based framework [7].

For cholesterol, the reclassification arithmetic is similarly stark. A 2024 JAMA analysis examining the AHA's PREVENT risk equations projected that the updated equations would shift millions of adults into or out of statin eligibility, depending on their broader risk profile [8]. The direction of the shift varies by age and sex: younger adults, particularly women, may see expanded eligibility, while some older adults may actually lose their indication for treatment under models that weigh competing mortality risks.

The populations most affected by reclassification are often the least equipped to act on it. Minority patients are more likely to report cost-related nonadherence to cardiovascular medications [9]. In 38 low- and middle-income countries, only 22.7% of patients with cardiovascular disease achieve antihypertensive treatment targets, and only 13.6% meet statin targets [10]. Even in the United States, where generic statins cost as little as $4 per month and basic antihypertensives under $5 per year, barriers of insurance coverage, transportation, and clinical access mean that reclassified risk does not automatically translate into treatment [9].

The Evidence Behind "Lower for Longer"

The scientific case for tighter thresholds rests on several independent lines of evidence. The most influential is the SPRINT trial (Systolic Blood Pressure Intervention Trial), a randomized controlled trial of 9,361 adults at elevated cardiovascular risk. SPRINT found that targeting a systolic blood pressure below 120 mmHg, rather than the standard target of below 140, reduced major adverse cardiovascular events by 25% and all-cause mortality by 27% [11]. The trial was stopped early because the benefits in the intensive-treatment arm were so pronounced.

A subsequent modeling study estimated that nationwide adoption of SPRINT-level targets could prevent a substantial number of cardiovascular deaths per year [12]. But the intensive arm also produced higher rates of hypotension, syncope, electrolyte abnormalities, and acute kidney injury [11] — a tradeoff that lies at the center of the overtreatment debate.

For cholesterol, the most compelling recent framework is the "LDL cumulative exposure hypothesis," articulated in a 2024 review in Nature Reviews Cardiology by Brian Ference, Eugene Braunwald, and Alberico Catapano [13]. The hypothesis holds that atherosclerotic cardiovascular disease depends not just on current LDL-C levels but on the total lifetime burden of LDL particles passing through arterial walls. The biological mechanism is well established: LDL particles smaller than 70 nanometers cross the endothelial barrier and become trapped in the arterial wall, triggering an inflammatory cascade that gradually builds atherosclerotic plaque [14].

Mendelian randomization studies — which use naturally occurring genetic variants as proxies for lifelong exposure — provide the strongest evidence for this model. A landmark analysis found that people with genetic variants conferring lifelong lower LDL-C experienced a 54.5% reduction in coronary heart disease risk per 1 mmol/L (38.7 mg/dL) lower LDL-C [15]. That is roughly three times the risk reduction seen when statins are started later in life to achieve the same LDL-C decrease — suggesting that duration of exposure matters as much as magnitude.

Source: OpenAlex

Data as of Jan 1, 2026CSV

The research base has expanded rapidly. According to OpenAlex data, publications on cholesterol, cardiovascular risk, and thresholds grew from roughly 1,650 per year in 2011 to over 12,300 in 2025, reflecting both heightened scientific interest and the proliferation of large-scale genetic and imaging datasets.

Supporting evidence also comes from imaging. MRI-based studies of carotid plaques have identified features — intraplaque hemorrhage, lipid-rich necrotic cores, fibrous cap rupture — that predict clinical events and correlate with cumulative LDL exposure [16]. Measurements of carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis, show graded associations with LDL-C levels even in ranges traditionally considered safe [17].

The Overtreatment Counterargument

Not all cardiologists and epidemiologists accept that lower thresholds serve patients well. The strongest counterargument is straightforward: lowering a diagnostic threshold classifies more people as sick, and the marginal benefit of treating those at the boundary is small while the harms of medication are real.

For statins, the adverse event profile is better characterized than commonly understood. A 2026 Lancet analysis found that 62 of 66 commonly reported statin side effects lacked support from reliable clinical evidence [18]. The true prevalence of clinically significant statin intolerance — primarily myopathy — is estimated at 6 to 10% worldwide [19]. But perceived side effects drive nonadherence at far higher rates: as many as half of patients reduce, stop, or take statins irregularly because of reported muscle pain, much of which may reflect the nocebo effect [19].

For blood pressure, the SPRINT results themselves carry caveats. The trial excluded patients with diabetes and prior stroke — two of the highest-risk populations. The measurement protocol used unattended automated office blood pressure, which produces readings roughly 5 to 10 mmHg lower than typical clinical measurements, meaning the "120 target" in SPRINT may correspond to a higher number in routine practice [20]. Critics argue this makes the SPRINT targets appear more aggressive than they are in real-world application.

A broader concern comes from the medical overdiagnosis literature. A 2020 review in BMC Medicine argued that repeatedly lowering disease thresholds expands the pool of patients labeled as ill, increases healthcare expenditure, and exposes more people to medication side effects and the psychological burden of a chronic diagnosis — all without proportional gains in population health [21]. The 2017 hypertension guideline reclassification offers a case study: the 31.1 million newly labeled hypertensive adults included many whose 10-year cardiovascular risk was below the threshold at which medication clearly outweighs its risks [4].

Industry Ties and the Question of Independence

Threshold revisions carry enormous commercial stakes. Global statin sales alone exceeded $13 billion annually at their peak, and the market for PCSK9 inhibitors and other newer lipid-lowering agents continues to expand. Each downward revision of LDL targets potentially adds millions of patients to the treatment-eligible population.

This creates an unavoidable conflict-of-interest question. An analysis of the 2013 ACC/AHA cholesterol guideline found that 11 of 15 panel members had received funding from pharmaceutical companies that manufacture statins or related drugs [22]. The Institute of Medicine recommends that guideline chairs should have no conflicts of interest, and that at least half of panel members should be free of industry ties — a standard the 2013 panel did not meet [22].

Industry-sponsored statin trials tend to report larger treatment effects than independently funded studies. A 2014 network meta-analysis published in the BMJ found systematic differences in reported LDL-C reductions between industry-sponsored and independently funded randomized trials [23]. The authors did not allege fraud but noted that design choices — patient selection, comparator arms, outcome definitions — could produce favorable results without overt manipulation.

The 2026 ACC/AHA dyslipidemia guideline writing committee has disclosed its members' financial relationships, and the ACC/AHA conflict-of-interest policy has been tightened since 2013 [1]. Whether these reforms are sufficient remains a matter of debate. STAT News and other outlets have continued to document financial ties between guideline authors and pharmaceutical manufacturers [24].

Historical Precedent: What Happened When Thresholds Shifted Before

The 2017 hypertension reclassification is itself now old enough to evaluate. The longitudinal data is encouraging, if incomplete. A study of 373,800 hypertensive adults followed for a median of 11 years found that those who met the 2017 guideline's tighter blood pressure targets experienced a 23% reduction in cardiovascular events, comparable to the 27% reduction seen in the SPRINT trial [7].

Diabetes diagnosis offers another instructive precedent. In 2003, the American Diabetes Association lowered the impaired fasting glucose threshold from 110 mg/dL to 100 mg/dL, substantially expanding the prediabetes population [25]. In 2010, the ADA added HbA1c of 5.7% to 6.4% as an additional prediabetes criterion [26]. These changes reclassified roughly one-third of U.S. adults as prediabetic. Whether the reclassification improved outcomes is debated: evidence shows that early identification enables lifestyle interventions that reduce progression to diabetes, but population-level cardiovascular benefits have been harder to demonstrate definitively over follow-up periods [25].

The pattern is consistent: threshold changes generate initial controversy, expand the treatment-eligible population, and produce measurable but modest benefits concentrated among those closest to the old cutoff. The question is whether the aggregate benefit justifies the aggregate cost and harm.

The Gap Between Evidence and Guidelines

Professional bodies have not moved in lockstep with the research. The AHA and ACC published the SPRINT results in 2015, but it took until 2017 for hypertension guidelines to incorporate the findings — a two-year lag during which the evidence was available but not codified in clinical recommendations [3]. The 2026 dyslipidemia guideline replaced a 2018 version, incorporating studies published through April 2025 — an eight-year cycle [1].

The European Society of Cardiology has operated on a similar timeline, with its 2019 dyslipidemia guideline updated in 2025 [2]. These lags are not arbitrary. Guideline committees convene systematic evidence reviews, solicit public comment, and navigate internal disagreements. But the practical effect is that millions of patients receive care under outdated risk thresholds for years after better evidence becomes available.

The 2025 AHA/ACC hypertension guideline addressed this gap in part by introducing the PREVENT risk calculator, which incorporates social determinants of health and kidney function to produce more individualized risk estimates [5]. This represents a move away from single-number thresholds toward risk-stratified treatment decisions — a framework that, if widely adopted, could reduce both undertreatment of high-risk patients and overtreatment of low-risk ones.

What Remains Uncertain

The cumulative-exposure model of LDL-driven atherosclerosis is well supported by Mendelian randomization and imaging data, but several questions remain open. Most Mendelian randomization studies rely on European-ancestry cohorts, limiting their generalizability [15]. The imaging evidence — carotid IMT, coronary calcium scoring, MRI plaque characterization — is strong in cross-sectional analyses but has limited long-term randomized trial data confirming that intervening on imaging-detected subclinical disease improves hard outcomes [16].

For blood pressure, the optimal target for patients over 80, those with diabetes, and those with chronic kidney disease remains contested. SPRINT excluded diabetic patients, and the ACCORD trial — which tested intensive blood pressure control in diabetics — showed only a 12% cardiovascular risk reduction, less than half of SPRINT's effect [11].

The financial modeling of expanded treatment eligibility is also incomplete. Generic statins and basic antihypertensives are inexpensive, but the downstream costs of expanded screening, monitoring, specialist referrals, and second-line therapies for the newly reclassified population have not been comprehensively estimated. For uninsured and underinsured Americans, even a $4 monthly copay can be a barrier — and the real cost is in the time and access required for regular medical follow-up [9].

The Bottom Line

The science supporting lower cholesterol and blood pressure thresholds is substantial and growing. The LDL cumulative exposure model, the SPRINT trial results, and multiple guideline revisions across the ACC/AHA and ESC/EAS all point in the same direction: levels once considered safe carry real, quantifiable risk. But the translation of that evidence into clinical practice raises legitimate concerns about overdiagnosis, industry influence, and health equity that the guidelines themselves have only partially addressed. For the tens of millions of adults whose numbers now fall in the gray zone between old and new thresholds, the answer depends on individual risk profiles that no single cutoff can capture.